Oncoshot

Next week, I’ll be in San Francisco during one of healthcare’s most influential gatherings, the JP Morgan Healthcare Conference #JPM2025. This year, AI in Healthcare and Life Sciences will continue to take center stage, and Oncoshot is proud to be part of the conversation. As Asia's leading health insights exchange platform, we're tackling the most complex data challenges in oncology through the power of advanced technologies. Our solutions leverage data extraction automation and oncology fine-tuned LLMs to empower cancer centres with streamlined data management, foster stronger collaborations between healthcare systems and industry, and connect patients with cutting-edge clinical trials and research. If you’re interested in exploring collaborations, let’s connect in person in San Francisco next week! #JPM2025 #OncologyResearch #AIinHealthcare #ClinicalInnovation #FutureOfHealthcare Ruslan Enikeev Chee Yong Chua Dr. Nilesh Atre Andrew Wilson Yigit Yucel Oncoshot Oncoshot India Enterprise Singapore JLABS Nicole A. Pang Xue Bin Derek Neo Alessandro Falcone, MD Ronne Yeo Kenneth Goh Anvesh Ramineni Cheryl Teo

AI in Healthcare: Evolving SaaS, Unlocking Potential Looks like the tech world came back from the new year holidays, watched Microsoft CEO Satya Nadella's video on "SaaS is Dead," and went on overdrive. While the headline grabs attention, the reality to me isn’t about SaaS disappearing—it’s about evolution. SaaS, the backbone of cloud-delivered software, is being transformed by AI. In healthcare, this shift unlocks exciting possibilities to enhance clinical, research, and operational workflows. Hesitation to Adoption: The Role of Healthcare-Compliant Infrastructure My experience across the region is that healthcare systems, particularly large public centers, have historically been cautious about SaaS adoption. Concerns around data privacy, security, and regulatory compliance (like GDPR and HIPAA) have (?rightfully) slowed progress . But advancements in healthcare-compliant cloud infrastructure are changing this. These systems meet the rigorous standards of the healthcare industry while creating a foundation for safe, secure, and scalable innovation. AI Enhances SaaS: Smarter, More Adaptive Platforms AI doesn’t replace SaaS, it amplifies its potential. Instead of limiting users to static dashboards or rigid workflows, AI enables dynamic data interactions. Imagine clinicians crafting tailored queries to find eligible patient cohorts for clinical trials or analyzing real-world survival outcomes, rather than being confined to pre-set views. While practical challenges like costs and computational demands remain, the potential for AI to make systems smarter, more adaptive, and more impactful is immense. The Logic Layer: The Foundation for Responsible AI At the heart of this transformation lies the logic layer—a critical component that ensures data is not only stored but also structured, enriched, and maintained for usability and reliability. This layer is essential to validate AI outputs, reduce risks like hallucinations, and build stakeholder trust by turning raw data into actionable insights. At Oncoshot, we’re building this foundation with tools like OS-EXTA, OS-ENRA, and OS-MAIA, which integrate automated data extraction with oncology-specific AI/LLM models which can be deployed within a federated cloud environment that is controlled by hospitals. These tools help construct the logic layer that healthcare systems need to responsibly deploy AI. Whether it’s structuring clinical, operational, or diagnostic data, this infrastructure is key to unlocking AI’s full potential in healthcare. The convergence of AI and healthcare-compliant infrastructure is redefining what’s possible in care delivery, research, and operations. With the right systems in place, we’re on the cusp of a future where technology isn’t just a tool but a trusted partner in transforming healthcare. These are exciting times. #AIinHealthcare #Innovation #SaaS #Oncology #Collaboration #Research #ClinicalTrials #RWE

2024 - Drenched, tired and a tad crazy. But we're all still smiling :) As 2024 comes to a close, I’m reflecting on a year of resilience and progress for Oncoshot. Despite the challenging climate for startups, we’ve made significant financial and operational strides. More than ever, I'm confident in Oncoshot’s vision and impact as we lay the groundwork for a future where oncology research is efficient, cost-effective, and near-realtime health data sharing between healthcare systems and innovators can be a reality. Some highlights from this year: 1. Empowering Hospitals with Better Data This year, we strengthened our value proposition for hospitals with technologies for automated data extraction and restructuring of clinical data. By addressing long-standing barriers to entry (ie manpower to restructure data), we’ve made it easier for hospitals to manage research data effectively. Starting in APAC, this approach is now gaining traction with hospital partners in US, UK, and EU, underscoring the global demand for better systems. The coming 6 mths will be focused on executing data pipelines for 3 large health system partners globally. 2. Strengthening Industry Collaboration We proudly launched Singapore’s first industry-supported tumor registry, proving how public-private partnerships can unlock new opportunities and reshape oncology research. I'm excited about how we are collectively building new models of #RWE consumption with more real-time aggregate insights sharing. While we look to bring more industry partners to participate in the ongoing projects in Singapore, we are also in the midst of strategising new projects with the same innovative industry partners across other health systems outside SG. 3. Innovating for the Future, Today. A major milestone this year was the launch of RecommendTx, our oncology-tuned LLM solution that matches cancer patients with clinical trials. In the coming year, we will be doubling down on our fine-tuned LLM model to expand its capabilities across RWE - expanding the power of our LLM and to deploy this LLM locally in a cost efficient model. We are delighted to partner with the likes of Amazon Web Services (AWS) as a public sector partner to make our LLM available in a federated and affordable manner for our hospitals. As I reflect, I am deeply grateful to everyone who has been part of this journey. Your support has been critical in empowering our vision to transform cancer data and research. Here’s to 2025—a year of more innovation, collaboration, and breakthroughs. Wishing you all a Happy New Year! 🎉 #Innovation #Oncology #Collaboration #NewYear2025 #Healthcare   Oncoshot Oncoshot India Ruslan Enikeev Chee Yong Chua Dr. Nilesh Atre Andrew Wilson Thanuja Naidu Yigit Yucel

Harnessing AI to Transform Clinical Development It was great to have participated in the "Harnessing AI and Digital Technology to Accelerate Clinical Development" panel discussion at #JLABS Singapore two weeks ago. James Gallagher, Head of Early Innovation at Johnson & Johnson, provided a clear and compelling overview of how AI is transforming clinical trials—from smarter design to enhanced patient recruitment. A/Prof Danny Soon, CEO of Consortium for Clinical Research and Innovation, Singapore (CRIS) and Singapore Clinical Research Institute (SCRI), shared public sector insights on drivers of progress in Singapore’s clinical research ecosystem. Sharon Chen, CEO of AlphaLife Sciences, shared examples on how #GenAI is revolutionizing clinical workflows for biopharma, highlighting the rapid innovation in this space to improve efficiency.. I had the chance to discuss how AI can enable trusted and efficient extraction and management of healthcare data to support clinical development. There’s still much to be done on the data front—ensuring accessibility, quality, and readiness to truly unlock AI’s full potential. That said, we’re at a remarkable point in time, with immense opportunities to collaborate and advance clinical development like never before. A big thank you to Alessandro Falcone, MD, Head JLABS Singapore, and Sharon Chan, VP JLABS APAC, for organizing such a dynamic and impactful event. Bringing together public and private stakeholders, pharma, and startups is exactly what’s needed to drive innovation and deliver better outcomes for patients. Excited for what’s next! #AIinHealthcare #ClinicalInnovation Oncoshot #JLABSSingapore #Collaboration #DigitalHealth #ClinicalTrials #PharmaInnovation Kenneth Goh Ran Tao Sravanthy Manesh Ruslan Enikeev Chee Yong Chua Yigit Yucel Germaine L Megan Chu Mei Kan Dr. Nilesh Atre Andrew Wilson Shabbir Syed Abdul Zubin Daruwalla Bernard Ng Simon Hopkins

A recent article in The Straits Times has ignited crucial conversations about #Singapore's cancer care strategies, spotlighting the urgent need to address our rapidly evolving healthcare ecosystem. While the outcomes reported in the particular industry-sponsored white paper may have been misrepresented, the debate raises critical questions about our approach to cancer care and population health as a whole. Over the past three years, Singapore's national press has covered a range of pressing topics, from the soaring costs of cancer treatment to the challenges patients face in accessing life-saving therapies amidst a backdrop of rapidly advancing technologies and innovations. These discussions present a unique opportunity to ask deeper questions about the role of data in transforming our legacy reactive approaches into a more proactive and dynamic system. #cancer #pophealth #RWE Ruslan Enikeev Chee Yong Chua Zubin Daruwalla Devanathan Raghunathan PhD MBA Clive Tan

How do we solve oncology’s toughest data challenges? Last week, we brought together some of the top oncology experts to tackle this question head-on. Here's what we uncovered: 𝗗𝗮𝘁𝗮 𝗜𝘀𝘀𝘂𝗲𝘀 𝗔𝗿𝗲 𝗦𝗹𝗼𝘄𝗶𝗻𝗴 𝗗𝗼𝘄𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Siloed platforms and manual data extraction require significant labor, creating inefficiencies that delay clinical trials and real-world evidence studies. In fact, more than 80% of clinical trials fail to enroll on time, resulting in study extensions or the addition of new study sites. (1) 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗮𝘁𝗮 𝗶𝘀𝗻’𝘁 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘇𝗲𝗱 𝗮𝗰𝗿𝗼𝘀𝘀 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 A staggering 97% of healthcare data goes unused because it’s unstructured. Inconsistent and incomplete data limit the progress in research. (2) 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗱𝗮𝘁𝗮 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝗼𝘂𝘁𝗱𝗮𝘁𝗲𝗱 𝗾𝘂𝗶𝗰𝗸𝗹𝘆 Patient records often miss critical updates, such as new treatments or diagnoses. This lack of up-to-date information leads to unreliable insights. When these challenges persist, they cause delays, wasted resources, and diminished trust in data accuracy—roadblocks that oncology research can’t afford. 𝗛𝗼𝘄 𝗧𝗼 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗲 𝗧𝗵𝗲𝘀𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀? The good news is that today’s technology can help solve these problems in a 𝘀𝗲𝗰𝘂𝗿𝗲, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲, 𝗮𝗻𝗱 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲 way. At Oncoshot, we’ve developed solutions that empower hospitals and researchers to overcome these challenges head-on. They work seamlessly within existing healthcare systems, saving time, improving accuracy, and accelerating oncology research. A big 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to everyone who joined our discussions last week and shared their valuable insights—your expertise is helping drive meaningful solutions in oncology research. Join the conversation! Reach out to us on support@oncoshot.com to learn more. (1) "Recruitment and retention of participants in clinical studies: Critical issues and challenges", Mira Desai, 2020 (2) "The Current State of AI in Healthcare and Where It's Going in 2023", HealthTech Magazine, 2023

In an era where clinical trials require more efficient and streamlined processes to reduce complexity and enhance accuracy, AI is well-positioned to make a significant impact. 🤝 A/Prof Danny Soon, CEO CRIS and Executive Director of Singapore Clinical Research Institute (SCRI), together with esteemed panelists Dr Huren Sivaraj, CEO and Co-Founder, Oncoshot and Sharon Chen, CEO and Co-Founder, AlphaLife Sciences, spoke on the topic "Harnessing AI and digital technology to accelerate clinical development" at a panel organised by JLABS Singapore on 5 December 2024. In his introduction, A/Prof Danny Soon referenced the example of Nobel Prize winner for Chemistry, Demis Hassabis, a former child chess prodigy who founded AI company DeepMind which developed AlphaZero, a learning algorithm that revolutionised computer chess. In the same vein, he highlighted the immense potential for AI to speed up operational aspects of #clinicaltrials and enhance the use of digital biomarkers in healthcare. The panellists highlighted the power of AI in enhancing data management in #clinicalresearch, and emphasised the need for robust data governance, security features, and regulations for AI to bring valuable impact for good. They also agreed on how closer collaboration from both the life sciences industry and healthcare providers can further the possibilities of novel use-applications of AI in future. The session was opened by Dr Alessandro Falcone, MD, Head, JLABS Singapore, Johnson & Johnson, and the panel was moderated by James Gallagher, Head of Early Innovation – Innovative Health, Global Development, Johnson & Johnson Innovative Medicine. At this final panel for the year, panellists shared their inspiring take on “the dream AI product’ that will have the most significant impact on the future of #clinicaldevelopment in future: ⚛️ Dr Huren Sivaraj shared the potential for AI to develop up-to-date use-cases to enhance insights for healthcare professionals amid an ever-evolving landscape of clinical trials, to better serve patients and match them to clinical trials that are suited for them. ⚛️ Ms Sharon Chen shared her hopes for the potential for next #GenAI to introduce automation to generate research reports and improve efficiencies, as well as for AI capabilities to comb through troves of publications and scour for unique insights that will highlight learnings from past examples to apply better strategies and study design to improve overall success rate of clinical studies in future. ⚛️ A/Prof Danny Soon shared how AI capabilities can support in-depth data-driven analysis of research proposals and portfolio submissions to enable more strategic approaches to support evaluation process and decision-making in the long run.

“What excites you most about the advancements in AI?” At the "Harnessing AI and Digital Technology to Accelerate Clinical Development" panel by JLABS Singapore, Dr. Huren Sivaraj addressed this question and more, sharing how AI is reshaping healthcare. Through Oncoshot, we’re leveraging AI to bridge critical gaps in the healthcare ecosystem, provide efficient and timely access to structured data, enhance patient matching for clinical trials, and generate actionable insights for all partners. These innovations are accelerating meaningful progress in oncology research—and we’re just getting started! A big thank you to Danny Soon and Sharon Chen for their inspiring insights, and to JLABS, Alessandro Falcone, MD, and James Gallagher for hosting such an impactful and thought-provoking final event of the year. Here’s to pushing the boundaries of innovation in 2025! #AIinHealthcare #JLABSSG  #OncologyInnovation #ClinicalTrials #HealthcareTransformation #OncologyResearch #ClinicalTrialInnovation #DigitalHealth #PrecisionOncology #HealthTech #AsiaHealthcare #CancerResearch

We're excited to share that our CEO, Dr. Huren Sivaraj, will be part of an expert panel at JLABS' event on December 5th in Singapore. Join us for a thought-provoking panel discussion on how #AI and digital technologies are revolutionizing life sciences—empowering faster patient recruitment, streamlining clinical trials, and addressing the most pressing challenges in clinical research today. Dr. Huren will be joined by distinguished leaders: - Danny Soon, Chief Executive Officer at the Consortium for Clinical Research and Innovation Singapore (CRIS) - Sharon Chen, CEO of AlphaLife Sciences Moderated by James Gallagher, Head of Early Innovation at Johnson & Johnson Innovative Medicine, this session promises insights into emerging innovations in clinical development. If you're attending the #ESMO Asia Congress or in Singapore, don't miss this opportunity to hear from industry leaders. 📅 Mark your calendar and RSVP here: https://lnkd.in/eFUJB2kn #HealthcareInnovation #ClinicalTrials #DigitalHealth #Oncology #OncologyResearch #AI Huren Sivaraj Ruslan Enikeev Chee Yong Chua Megan Chu Mei Kan Germaine L Thanuja Naidu Shabbir Syed Abdul Andrew Wilson Dr. Nilesh Atre Yigit Yucel Ruhi Reddy Arpita Chavan Tam C. Nguyen David Chia Oncoshot India

🎉 Oncoshot Turns 6! 🎉 Six years ago today, Oncoshot was founded by Dr. Huren Sivaraj and Ruslan Enikeev with a bold vision: to bridge the gap between cancer patients and innovative clinical trials. In an industry where only 3-5% of cancer patients participate in clinical trials, we set out to dramatically improve these numbers.  Along the way, we learned that tackling oncology’s complexities means empowering hospitals, doctors, researchers and patients with the right tools.  🚀 Our Journey So Far: - Partnered with top cancer institutions in Singapore to redefine the process of oncology research.  - Expanded into Australia, India, Taiwan, and beyond to support global trials, to build a privacy-safe platform with 20+ healthcare systems and 120,000+ patient records.  - Established tech licensing partnerships in high-volume clinical trial hubs like China and  Japan  - Tackled fragmented medical data problem with our AI-powered tool Recommend Tx, turning unstructured data into organized patient registries and matching patients to eligible trials. Today, Oncoshot is uniquely positioned to solve some of the most pressing challenges in oncology clinical trials: ✅ A robust regional network in the healthcare industry  ✅ Advanced technology harnessing AI to unlock the power of unstructured medical data  ✅ A passionate and experienced team driven by the mission to accelerate oncology research Our journey has only just begun. We’re inspired by the progress we’ve made, but even more by the potential ahead—to make every clinical trial more accessible, every patient match more efficient, and every breakthrough closer to reality. This would not have been possible without the incredible support of:   ✨ Our team, whose dedication drives our mission forward ✨ Our institutional investors, who believed in our vision from the start - MassMutual Ventures SEEDS Capital Lion City Capital Milltrust International ✨ Our partners, who trust us to innovate with them - including Enterprise Singapore Invest Victoria Nex Cubed JLABS Singapore Memorial Sloan Kettering Cancer Center ACatalyst Buzzreach Inc. To everyone who has been part of this journey—thank you. Here’s to continuing our mission to transform oncology research for the better. 🚀 Huren Sivaraj Ruslan Enikeev Chee Yong Chua Megan Chu Mei Kan Germaine L Yigit Yucel Thanuja Naidu David Chia Dr. Nilesh Atre SShabbir Syed Abdul Andrew Wilson Tam C. Nguyen Prajakta Koli Ilia Andreev Alexander Katkov Sergey Mihaylov Andrey Gonostarev Ruhi Reddy Arpita Chavan Diane C. Galistan Oncoshot India #OncologyInnovation #ClinicalTrials #HealthcareTransformation #OncologyResearch #ClinicalTrialInnovation #DigitalHealth #PrecisionOncology #HealthTech #AsiaHealthcare #CancerResearch